KCR is a Contract Research Organization (CRO) providing clinical development solutions for the pharmaceutical, biotechnology and medical device industries.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

ASCENTAGE PHARMA ANNOUNCES ITS 9TH ORPHAN DRUG DESIGNATION FROM THE US FDA IN 2020

Ascentage Pharma | January 05, 2021

news image

Ascentage Pharma (6855.HK), an internationally engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignancies, persistent hepatitis B (CHB), and age-related sicknesses, today reported that the US Food and Drug Administration (FDA) has allowed an Orphan Drug Designation (ODD) to the organization's novel Bcl-2 inhibitor, APG-2575, for the therapy of patients with intense myeloid leukemia (AML). This is the fourth ODD allowed to APG-2575 by the US FD...

Read More

HEMOGENYX PHARMACEUTICALS PLC SIGNED BIOLOGICAL INVESTIGATION AND MATERIAL SUPPLY AGREEMENT WITH ELI LILLY

Hemogenyx Pharmaceuticals | July 14, 2020

news image

On 26 June 2020 the Company announced a Development Agreement with a global pharmaceutical company ("GlobalCo"). GlobalCo has now consented to the use of its name in the announcement, an updated version of which is shown below. Hemogenyx Pharmaceuticals plc is pleased to announce that it has signed a Biological Investigation and Material Supply Agreement ("Agreement") with Eli Lilly and Company ("Lilly"), a leading global pharmaceutical company engage...

Read More

Pharmacy Market

NARRATIVA RAISES $1.3M TO HELP PHARMA COMPANIES ACCELERATE THE FDA DRUG APPROVAL PROCESS

Narrativa | May 19, 2021

news image

Narrativa, which has developed an artificial intelligence (AI) medical writing platform to assist pharmaceutical firms in speeding up drug approval and lowering overall compliance costs, recently completed a $1.3 million funding round. The Los Angeles-based firm currently uses its SaaS platform to automate the production of Clinical Study Reports (CSRs) and other regulatory reports for several pharmaceutical firms and other clinical research organizations (CROs). Th...

Read More

EPIGENETIC CHANGES MAKE BREAST CANCER CELLS DRUG RESISTANT

LabRoots | January 20, 2020

news image

Changes in the epigenetics - the modifiable chemical tags that can change the genome and gene expression - of breast cancer cells can make them resistant to drugs that are targeting them. This seems to happen to ER+ breast cancer cells, which make up around two of every three cases of breast cancer. This type of cancer can become resistant to the hormonal therapy used to treat it. Breast cancer relapse could be reduced, researchers suggested, if these epigenetic changes can be reversed. Re...

Read More
news image

Pharmacy Market

ASCENTAGE PHARMA ANNOUNCES ITS 9TH ORPHAN DRUG DESIGNATION FROM THE US FDA IN 2020

Ascentage Pharma | January 05, 2021

Ascentage Pharma (6855.HK), an internationally engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignancies, persistent hepatitis B (CHB), and age-related sicknesses, today reported that the US Food and Drug Administration (FDA) has allowed an Orphan Drug Designation (ODD) to the organization's novel Bcl-2 inhibitor, APG-2575, for the therapy of patients with intense myeloid leukemia (AML). This is the fourth ODD allowed to APG-2575 by the US FD...

Read More
news image

HEMOGENYX PHARMACEUTICALS PLC SIGNED BIOLOGICAL INVESTIGATION AND MATERIAL SUPPLY AGREEMENT WITH ELI LILLY

Hemogenyx Pharmaceuticals | July 14, 2020

On 26 June 2020 the Company announced a Development Agreement with a global pharmaceutical company ("GlobalCo"). GlobalCo has now consented to the use of its name in the announcement, an updated version of which is shown below. Hemogenyx Pharmaceuticals plc is pleased to announce that it has signed a Biological Investigation and Material Supply Agreement ("Agreement") with Eli Lilly and Company ("Lilly"), a leading global pharmaceutical company engage...

Read More
news image

Pharmacy Market

NARRATIVA RAISES $1.3M TO HELP PHARMA COMPANIES ACCELERATE THE FDA DRUG APPROVAL PROCESS

Narrativa | May 19, 2021

Narrativa, which has developed an artificial intelligence (AI) medical writing platform to assist pharmaceutical firms in speeding up drug approval and lowering overall compliance costs, recently completed a $1.3 million funding round. The Los Angeles-based firm currently uses its SaaS platform to automate the production of Clinical Study Reports (CSRs) and other regulatory reports for several pharmaceutical firms and other clinical research organizations (CROs). Th...

Read More
news image

EPIGENETIC CHANGES MAKE BREAST CANCER CELLS DRUG RESISTANT

LabRoots | January 20, 2020

Changes in the epigenetics - the modifiable chemical tags that can change the genome and gene expression - of breast cancer cells can make them resistant to drugs that are targeting them. This seems to happen to ER+ breast cancer cells, which make up around two of every three cases of breast cancer. This type of cancer can become resistant to the hormonal therapy used to treat it. Breast cancer relapse could be reduced, researchers suggested, if these epigenetic changes can be reversed. Re...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us